JP2018536012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536012A5 JP2018536012A5 JP2018532532A JP2018532532A JP2018536012A5 JP 2018536012 A5 JP2018536012 A5 JP 2018536012A5 JP 2018532532 A JP2018532532 A JP 2018532532A JP 2018532532 A JP2018532532 A JP 2018532532A JP 2018536012 A5 JP2018536012 A5 JP 2018536012A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heteroalkyl
- pharmaceutically acceptable
- functionalized payload
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 42
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 37
- 125000003342 alkenyl group Chemical group 0.000 claims description 34
- 125000000304 alkynyl group Chemical group 0.000 claims description 34
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- 125000000623 heterocyclic group Chemical group 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 28
- -1 alkoxyfluoroalkyl Chemical group 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000005647 linker group Chemical group 0.000 claims description 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 239000003937 drug carrier Substances 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000004442 acylamino group Chemical group 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 125000001769 aryl amino group Chemical group 0.000 claims description 5
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 5
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 5
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 5
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 2
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 2
- 229930183010 Amphotericin Natural products 0.000 claims description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- 108010078777 Colistin Proteins 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 108010013198 Daptomycin Proteins 0.000 claims description 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- 108010059993 Vancomycin Proteins 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 229960002749 aminolevulinic acid Drugs 0.000 claims description 2
- 229940009444 amphotericin Drugs 0.000 claims description 2
- 229960003942 amphotericin b Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 229940124346 antiarthritic agent Drugs 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000003409 antileprotic agent Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003435 antirheumatic agent Substances 0.000 claims description 2
- 239000003699 antiulcer agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- 229960004755 ceftriaxone Drugs 0.000 claims description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 2
- 229960000590 celecoxib Drugs 0.000 claims description 2
- 229940106164 cephalexin Drugs 0.000 claims description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 229960003346 colistin Drugs 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims description 2
- 229960005484 daptomycin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960003722 doxycycline Drugs 0.000 claims description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 229960000366 emtricitabine Drugs 0.000 claims description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 2
- 229960004413 flucytosine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims description 2
- 229960002014 ixabepilone Drugs 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 2
- 229960000715 nimodipine Drugs 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229960000988 nystatin Drugs 0.000 claims description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229960001237 podophyllotoxin Drugs 0.000 claims description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 2
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 2
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- 229960005404 sulfamethoxazole Drugs 0.000 claims description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001082 trimethoprim Drugs 0.000 claims description 2
- 229960003165 vancomycin Drugs 0.000 claims description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 16
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003470 adrenal cortex hormone Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
- 0 C[C@@](CSSCCOC(**)=O)NC(CC[C@](C(OC1/C=C/CCCCC1)=O)NC(c(cc1)ccc1NCc(cn1)nc2c1N=C(N)NC2=O)=O)=O Chemical compound C[C@@](CSSCCOC(**)=O)NC(CC[C@](C(OC1/C=C/CCCCC1)=O)NC(c(cc1)ccc1NCc(cn1)nc2c1N=C(N)NC2=O)=O)=O 0.000 description 44
- 239000011230 binding agent Substances 0.000 description 35
- 230000000295 complement effect Effects 0.000 description 21
- 238000000034 method Methods 0.000 description 16
- 125000000524 functional group Chemical group 0.000 description 15
- 239000002245 particle Substances 0.000 description 14
- 230000008685 targeting Effects 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 4
- 150000001345 alkine derivatives Chemical class 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 description 2
- ADBQDBLMIXMIOQ-ZAGVWLOFSA-N C[C@@H]([C@H]([C@H](C1)N)O)O[C@H]1O[C@@H](C[C@@](Cc1c(c(C(c2cccc(OC)c22)=O)c3C2=O)O)(/C(/CO)=N\NC(CCOC2CCC=CCCC2)=O)O)c1c3O Chemical compound C[C@@H]([C@H]([C@H](C1)N)O)O[C@H]1O[C@@H](C[C@@](Cc1c(c(C(c2cccc(OC)c22)=O)c3C2=O)O)(/C(/CO)=N\NC(CCOC2CCC=CCCC2)=O)O)c1c3O ADBQDBLMIXMIOQ-ZAGVWLOFSA-N 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- URYYVOIYTNXXBN-OWOJBTEDSA-N trans-cyclooctene Chemical compound C1CCC\C=C\CC1 URYYVOIYTNXXBN-OWOJBTEDSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HREOFOSOATWMJN-XRKVHMOMSA-N CC(C)(C)OC(N[C@H]([C@H](C(O[C@@H](C1)C(C)=C([C@H](C([C@](C)([C@H](C[C@H]2OC3)O)C([C@@H]4O)[C@@]23O)=O)O)C(C)(C)[C@@]14[O-2])=O)OC(OC1C=CCCCCC1)=O)c1ccccc1)=O Chemical compound CC(C)(C)OC(N[C@H]([C@H](C(O[C@@H](C1)C(C)=C([C@H](C([C@](C)([C@H](C[C@H]2OC3)O)C([C@@H]4O)[C@@]23O)=O)O)C(C)(C)[C@@]14[O-2])=O)OC(OC1C=CCCCCC1)=O)c1ccccc1)=O HREOFOSOATWMJN-XRKVHMOMSA-N 0.000 description 1
- RSVCUPVEPMGEGO-MKOFKEMZSA-N CC(OC[C@H]1O[C@@H](Cc2c(C[C@@H](CO3)C([C@@H]4c(cc5OC)cc(OC)c5OCc(cc5)ccc5NC(OC5C=CCCCCC5)=O)C3=O)c4cc3c2OCO3)[C@@H]2O)O[C@H]1[C@@H]2O Chemical compound CC(OC[C@H]1O[C@@H](Cc2c(C[C@@H](CO3)C([C@@H]4c(cc5OC)cc(OC)c5OCc(cc5)ccc5NC(OC5C=CCCCCC5)=O)C3=O)c4cc3c2OCO3)[C@@H]2O)O[C@H]1[C@@H]2O RSVCUPVEPMGEGO-MKOFKEMZSA-N 0.000 description 1
- HEYJCXJYGMGGGT-UHFFFAOYSA-N CCNC(OCc(cc1COC(NC)=O)cc(COC(NC)=O)c1NC(OC1C=CCCCCC1)=O)=O Chemical compound CCNC(OCc(cc1COC(NC)=O)cc(COC(NC)=O)c1NC(OC1C=CCCCCC1)=O)=O HEYJCXJYGMGGGT-UHFFFAOYSA-N 0.000 description 1
- ARCARSQGNUADLL-TZHIXCAUSA-N CCc1c(CN(C2=CC([C@@H]3O)=C4COC3=O)C4=O)c2nc(cc2)c1cc2OC(OC1C=CCCCCC1)=O Chemical compound CCc1c(CN(C2=CC([C@@H]3O)=C4COC3=O)C4=O)c2nc(cc2)c1cc2OC(OC1C=CCCCCC1)=O ARCARSQGNUADLL-TZHIXCAUSA-N 0.000 description 1
- QHDVORFXSYSMJE-LBAQZLPGSA-N CN(Cc(nc12)cnc1nc(NC(OC1C=CCCCCC1)=O)nc2N)c(cc1)ccc1C(N[C@@H](CCC(O)=O)C(O)=O)=O Chemical compound CN(Cc(nc12)cnc1nc(NC(OC1C=CCCCCC1)=O)nc2N)c(cc1)ccc1C(N[C@@H](CCC(O)=O)C(O)=O)=O QHDVORFXSYSMJE-LBAQZLPGSA-N 0.000 description 1
- IFTCLIQBFYWPDM-LBAQZLPGSA-N CN(Cc1nc2c(N)nc(N)nc2nc1)c(cc1)ccc1C(N[C@@H](CCC(O)=O)C(OC1C=CCCCCC1)=O)=O Chemical compound CN(Cc1nc2c(N)nc(N)nc2nc1)c(cc1)ccc1C(N[C@@H](CCC(O)=O)C(OC1C=CCCCCC1)=O)=O IFTCLIQBFYWPDM-LBAQZLPGSA-N 0.000 description 1
- HDQHBDWBILCGIY-LBAQZLPGSA-N CN(Cc1nc2c(NC(OC3C=CCCCCC3)=O)nc(N)nc2nc1)c(cc1)ccc1C(N[C@@H](CCC(O)=O)C(O)=O)=O Chemical compound CN(Cc1nc2c(NC(OC3C=CCCCCC3)=O)nc(N)nc2nc1)c(cc1)ccc1C(N[C@@H](CCC(O)=O)C(O)=O)=O HDQHBDWBILCGIY-LBAQZLPGSA-N 0.000 description 1
- AVLXZYPKKVLDJG-DQAQDFEYSA-N C[C@@H]([C@H]([C@H](C1)N)O)O[C@H]1O[C@@H](C[C@@](Cc1c2)(/C(/CO)=N\NC(CCCC(NNC(OC3C=CCCCCC3)=O)=O)=O)O)c1cc(C(c(c1ccc3)c3OC)=O)c2C1=O Chemical compound C[C@@H]([C@H]([C@H](C1)N)O)O[C@H]1O[C@@H](C[C@@](Cc1c2)(/C(/CO)=N\NC(CCCC(NNC(OC3C=CCCCCC3)=O)=O)=O)O)c1cc(C(c(c1ccc3)c3OC)=O)c2C1=O AVLXZYPKKVLDJG-DQAQDFEYSA-N 0.000 description 1
- PVVPRRNVYIENRY-WIGZPWCWSA-N C[C@@H]([C@H]([C@H](C1)NC(OC(CCC2)C=CCC2N2CCCCC2)=O)O)O[C@H]1O[C@@H](C[C@@](Cc1c(c(C(c2cccc(OC)c22)=O)c3C2=O)O)(C(CO)=O)O)c1c3O Chemical compound C[C@@H]([C@H]([C@H](C1)NC(OC(CCC2)C=CCC2N2CCCCC2)=O)O)O[C@H]1O[C@@H](C[C@@](Cc1c(c(C(c2cccc(OC)c22)=O)c3C2=O)O)(C(CO)=O)O)c1c3O PVVPRRNVYIENRY-WIGZPWCWSA-N 0.000 description 1
- COQCJBMSVWRRQU-VYPOZZEDSA-N C[C@H](C(C1O)O)O[C@H]1N(C=C(C(NC(OC1C=CCCCCC1)=O)=N1)F)C1=O Chemical compound C[C@H](C(C1O)O)O[C@H]1N(C=C(C(NC(OC1C=CCCCCC1)=O)=N1)F)C1=O COQCJBMSVWRRQU-VYPOZZEDSA-N 0.000 description 1
- KZDZFXYYGBLXPT-HKJXZACSSA-N C[C@H](CC(C(CCC([C@]1(C)C=C2)=CC2=O)[C@@]11F)[C@]2(C)C[C@@H]1O)[C@@]2(/C(/CO)=N\NC(CCCC(NNC(OC1C=CCCCCC1)=O)=O)=O)O Chemical compound C[C@H](CC(C(CCC([C@]1(C)C=C2)=CC2=O)[C@@]11F)[C@]2(C)C[C@@H]1O)[C@@]2(/C(/CO)=N\NC(CCCC(NNC(OC1C=CCCCCC1)=O)=O)=O)O KZDZFXYYGBLXPT-HKJXZACSSA-N 0.000 description 1
- YQBAKNCEEHNSSB-SOCWHVLBSA-N C[C@H](C[C@@H]([C@H](CCC([C@]1(C)C=C2)=C/C2=N/NC(CNC(OC2C=CCCCCC2)=O)=O)[C@@]11F)[C@]2(C)C[C@@H]1O)[C@@]2(C(CO)=O)O Chemical compound C[C@H](C[C@@H]([C@H](CCC([C@]1(C)C=C2)=C/C2=N/NC(CNC(OC2C=CCCCCC2)=O)=O)[C@@]11F)[C@]2(C)C[C@@H]1O)[C@@]2(C(CO)=O)O YQBAKNCEEHNSSB-SOCWHVLBSA-N 0.000 description 1
- DPPXURSLQDUVOF-ZVSRJETDSA-N C[C@H](C[C@@H]([C@H](CCC([C@]1(C)C=C2)=C/C2=N/NC(OC2C=CCCCCC2)=O)[C@@]11F)[C@]2(C)C[C@@H]1O)[C@@]2(C(CO)=O)O Chemical compound C[C@H](C[C@@H]([C@H](CCC([C@]1(C)C=C2)=C/C2=N/NC(OC2C=CCCCCC2)=O)[C@@]11F)[C@]2(C)C[C@@H]1O)[C@@]2(C(CO)=O)O DPPXURSLQDUVOF-ZVSRJETDSA-N 0.000 description 1
- KZDZFXYYGBLXPT-BYNBIIAQSA-N C[C@H](C[C@@H]([C@H](CCC([C@]1(C)C=C2)=CC2=O)[C@@]11F)[C@]2(C)C[C@@H]1O)[C@@]2(/C(/CO)=N\NC(CCCC(NNC(OC1C=CCCCCC1)=O)=O)=O)O Chemical compound C[C@H](C[C@@H]([C@H](CCC([C@]1(C)C=C2)=CC2=O)[C@@]11F)[C@]2(C)C[C@@H]1O)[C@@]2(/C(/CO)=N\NC(CCCC(NNC(OC1C=CCCCCC1)=O)=O)=O)O KZDZFXYYGBLXPT-BYNBIIAQSA-N 0.000 description 1
- OPCPGWAQNOSCBL-UHFFFAOYSA-N Cc(cc1)ccc1-c1cc(C(F)(F)F)n[n]1-c(cc1)ccc1S(NC(OC1C=CCCCCC1)=O)(=O)=O Chemical compound Cc(cc1)ccc1-c1cc(C(F)(F)F)n[n]1-c(cc1)ccc1S(NC(OC1C=CCCCCC1)=O)(=O)=O OPCPGWAQNOSCBL-UHFFFAOYSA-N 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- ORHFSTKRUYPYRV-HTLISINNSA-N NC(C=CN1[C@@H](C2(F)F)O[C@H](COC(OC3C=CCCCCC3)=O)C2O)=NC1=O Chemical compound NC(C=CN1[C@@H](C2(F)F)O[C@H](COC(OC3C=CCCCCC3)=O)C2O)=NC1=O ORHFSTKRUYPYRV-HTLISINNSA-N 0.000 description 1
- WIDDEMOIUCBFTQ-ANYOKISRSA-N Nc1nc(N)nc2c1nc(CN(C(OC1C=CCCCCC1)=O)c(cc1)ccc1C(N[C@@H](CCC(O)=O)C(O)=O)=O)cn2 Chemical compound Nc1nc(N)nc2c1nc(CN(C(OC1C=CCCCCC1)=O)c(cc1)ccc1C(N[C@@H](CCC(O)=O)C(O)=O)=O)cn2 WIDDEMOIUCBFTQ-ANYOKISRSA-N 0.000 description 1
- NEAXSKKSQSGPOD-UHFFFAOYSA-N O/N=C(/c1n[o]nc1NCCNS(NC(OC1C=CCCCCC1)=O)(=O)=O)\Nc(cc1Br)ccc1F Chemical compound O/N=C(/c1n[o]nc1NCCNS(NC(OC1C=CCCCCC1)=O)(=O)=O)\Nc(cc1Br)ccc1F NEAXSKKSQSGPOD-UHFFFAOYSA-N 0.000 description 1
- IDOHXAKSVRIXRF-UHFFFAOYSA-N O=C(N(C=C(C(N1)=O)F)C1=O)OC1C=CCCCCC1 Chemical compound O=C(N(C=C(C(N1)=O)F)C1=O)OC1C=CCCCCC1 IDOHXAKSVRIXRF-UHFFFAOYSA-N 0.000 description 1
- NOPIQXRJMYDQBC-UHFFFAOYSA-N O=C(N(Cc1ccc(C(F)(F)F)nc1)c1ccc(Cc2c[nH]c(nc3)c2cc3Cl)cn1)OC1=CCCCCCC1 Chemical compound O=C(N(Cc1ccc(C(F)(F)F)nc1)c1ccc(Cc2c[nH]c(nc3)c2cc3Cl)cn1)OC1=CCCCCCC1 NOPIQXRJMYDQBC-UHFFFAOYSA-N 0.000 description 1
- DSYQOIWRAZENCZ-HTLISINNSA-N OC[C@H](C(C1(F)F)O)O[C@H]1N(C=CC(NC(OC1C=CCCCCC1)=O)=N1)C1=O Chemical compound OC[C@H](C(C1(F)F)O)O[C@H]1N(C=CC(NC(OC1C=CCCCCC1)=O)=N1)C1=O DSYQOIWRAZENCZ-HTLISINNSA-N 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000001954 papillon Nutrition 0.000 description 1
- 244000229285 papillon Species 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216858P | 2015-09-10 | 2015-09-10 | |
| US62/216,858 | 2015-09-10 | ||
| US201562242896P | 2015-10-16 | 2015-10-16 | |
| US62/242,896 | 2015-10-16 | ||
| US201562387480P | 2015-12-24 | 2015-12-24 | |
| US62/387,480 | 2015-12-24 | ||
| US201662327924P | 2016-04-26 | 2016-04-26 | |
| US62/327,924 | 2016-04-26 | ||
| US201662344341P | 2016-06-01 | 2016-06-01 | |
| US62/344,341 | 2016-06-01 | ||
| US201662357647P | 2016-07-01 | 2016-07-01 | |
| US62/357,647 | 2016-07-01 | ||
| US201662381442P | 2016-08-30 | 2016-08-30 | |
| US62/381,442 | 2016-08-30 | ||
| PCT/US2016/051394 WO2017044983A1 (en) | 2015-09-10 | 2016-09-12 | Bioorthogonal compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021000729A Division JP2021073200A (ja) | 2015-09-10 | 2021-01-06 | 生体直交型組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536012A JP2018536012A (ja) | 2018-12-06 |
| JP2018536012A5 true JP2018536012A5 (enExample) | 2019-10-24 |
| JP6823067B2 JP6823067B2 (ja) | 2021-01-27 |
Family
ID=58240246
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532532A Active JP6823067B2 (ja) | 2015-09-10 | 2016-09-12 | 生体直交型組成物 |
| JP2021000729A Withdrawn JP2021073200A (ja) | 2015-09-10 | 2021-01-06 | 生体直交型組成物 |
| JP2025010747A Pending JP2025066807A (ja) | 2015-09-10 | 2025-01-24 | 生体直交型組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021000729A Withdrawn JP2021073200A (ja) | 2015-09-10 | 2021-01-06 | 生体直交型組成物 |
| JP2025010747A Pending JP2025066807A (ja) | 2015-09-10 | 2025-01-24 | 生体直交型組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10828373B2 (enExample) |
| EP (1) | EP3346997A4 (enExample) |
| JP (3) | JP6823067B2 (enExample) |
| CN (2) | CN117567535A (enExample) |
| AU (2) | AU2016321431C1 (enExample) |
| WO (1) | WO2017044983A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009045539A2 (en) * | 2007-10-05 | 2009-04-09 | Nektar Therapeutics Al, Corporation | Oligomer-corticosteroid conjugates |
| JP6823067B2 (ja) | 2015-09-10 | 2021-01-27 | タンボ・インコーポレイテッド | 生体直交型組成物 |
| AU2016353345B2 (en) | 2015-11-12 | 2021-12-23 | University Of Virginia Patent Foundation | Compositions and methods for vas-occlusive contraception and reversal thereof |
| KR20250114431A (ko) | 2016-11-08 | 2025-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| EP3565484B1 (en) | 2017-01-05 | 2024-04-03 | Contraline, Inc. | Compositions for implanting and reversing stimuli-responsive implants |
| US12383421B2 (en) | 2017-01-05 | 2025-08-12 | Contraline, Inc. | Contraceptive devices |
| ES2983582T3 (es) * | 2017-04-07 | 2024-10-23 | Tambo Inc | Composiciones bioortogonales |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| IL313068A (en) | 2017-11-07 | 2024-07-01 | Regeneron Pharma | Hydrophilic linkers for antibody drug conjugates |
| IL275757B2 (en) | 2018-01-08 | 2025-08-01 | Regeneron Pharma | Steroids and antibody-conjugates thereof |
| CN110577501A (zh) * | 2018-06-07 | 2019-12-17 | 江苏柯菲平医药股份有限公司 | 吲哚胺2,3-双加氧酶调节剂，其制备方法及用途 |
| CN110066253B (zh) * | 2018-01-24 | 2023-06-23 | 江苏柯菲平医药股份有限公司 | 1,2,5-噁二唑类衍生物，其制备方法及其在医药中的应用 |
| GB2585149B (en) * | 2018-01-24 | 2022-06-01 | Nanjing Carephar Shenghui Pharmaceutical Co Ltd | Modulator of indoleamine-(2.3)-dioxygenase, preparation method and use thereof |
| MX2020011546A (es) | 2018-05-09 | 2021-01-29 | Regeneron Pharma | Anticuerpos anti-msr1 y metodos de uso de los mismos. |
| WO2020010560A1 (zh) * | 2018-07-12 | 2020-01-16 | 深圳华大生命科学研究院 | 一种亚磷酰胺类化合物、其制备方法及应用 |
| EP3856255A1 (en) * | 2018-09-26 | 2021-08-04 | Ascendis Pharma A/S | Treatment of infections |
| IL282114B2 (en) * | 2018-10-10 | 2025-05-01 | Tambo Inc | Processes for preparing functional cyclooctanes |
| AU2019380413B2 (en) | 2018-11-13 | 2025-04-17 | Contraline, Inc. | Systems and methods for delivering biomaterials |
| CN111662251A (zh) * | 2019-03-05 | 2020-09-15 | 国家纳米科学中心 | 一种紫杉醇前药及其制备方法和应用 |
| JP7622031B2 (ja) * | 2019-07-05 | 2025-01-27 | タンボ・インコーポレイテッド | トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| CN111138337B (zh) * | 2019-12-26 | 2021-06-22 | 清华大学 | 用于生物正交反应的双环[4.1.0]庚烷亚硝基脲衍生物及其制备方法与应用 |
| SE2050204A1 (en) * | 2020-02-24 | 2021-08-25 | Oboe Ipr Ab | A system and method for releasing a species |
| CN113321692B (zh) * | 2020-02-28 | 2022-10-14 | 国家纳米科学中心 | 一种阿霉素前药及其制备方法和应用 |
| CN113321702B (zh) * | 2020-02-28 | 2022-08-05 | 国家纳米科学中心 | 一种单甲基澳瑞他汀f甲酯前药及其制备方法和应用 |
| CN113354657B (zh) * | 2020-03-05 | 2022-10-21 | 国家纳米科学中心 | 一种Mytoxin A前药及其制备方法和应用 |
| US12589162B2 (en) | 2020-08-07 | 2026-03-31 | Tambo, Inc. | Trans-cyclooctene prodrug of monomethyl auristatin E |
| US20250186592A1 (en) | 2021-10-29 | 2025-06-12 | Tambo, Inc. | Tetrazine conjugates for in vivo targeted delivery of a payload |
| JP2024543016A (ja) | 2021-10-29 | 2024-11-19 | タンボ・インコーポレイテッド | トランス－シクロオクテンコンジュゲート |
| WO2023081809A1 (en) | 2021-11-05 | 2023-05-11 | Tambo, Inc. | Trans-cyclooctene-modified bispecific antibodies |
| EP4590342A1 (en) | 2022-09-20 | 2025-07-30 | VALANX Biotech GmbH | Click-to-release on proteins and peptides |
| WO2024130526A1 (en) * | 2022-12-20 | 2024-06-27 | Nanjing University | A bioorthogonal cycloaddition reaction and use thereof |
| WO2024168065A1 (en) | 2023-02-08 | 2024-08-15 | Tambo, Inc. | System comprising modified whole cell payloads for targeted delivery |
| CN121001752A (zh) | 2023-02-21 | 2025-11-21 | 坦博公司 | 反式环辛烯缀合物 |
| WO2024210956A1 (en) * | 2023-04-05 | 2024-10-10 | Rutgers, The State University Of New Jersey | Biogel, compositions and methods of use the same |
| CN121419788A (zh) | 2023-05-04 | 2026-01-27 | 坦博公司 | 用于体内递送有效载荷的基于四嗪的靶向剂 |
| CN121419790A (zh) | 2023-05-18 | 2026-01-27 | 坦博公司 | 反式环辛烯修饰的靶向性蛋白质降解剂缀合物 |
| WO2025059685A1 (en) | 2023-09-15 | 2025-03-20 | Tambo, Inc. | Methods for in vivo targeted delivery of a payload |
| WO2025231424A1 (en) * | 2024-05-02 | 2025-11-06 | Arizona Board Of Regents On Behalf Of Arizona State University | Procapped mrna for targeted cell translation |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995031223A1 (en) | 1994-05-13 | 1995-11-23 | Kuraray Co., Ltd. | Medical polymer gel |
| ATE394412T1 (de) | 2001-06-21 | 2008-05-15 | Clontech Lab Inc | Wasserlösliche polymere zusammensetzungen mit affinität für metallionen und verfahren zu deren anwendung |
| WO2003084571A1 (en) | 2002-04-08 | 2003-10-16 | Denki Kagaku Kogyo Kabushiki Kaisha | Therapeutic composition for bone infectious disease |
| US7445894B2 (en) | 2002-05-03 | 2008-11-04 | Molecular Probes, Inc. | Compositions and methods for detection and isolation of phosphorylated molecules |
| EP1942950A2 (en) | 2005-11-01 | 2008-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Biodegradable composite for internal local radiotherapy |
| EP1867638A1 (de) | 2006-06-16 | 2007-12-19 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Verfahren zur kovalenten Verknüpfung zweier Moleküle mittels Diels-Alder-Reaktion mit inversem Elektronenbedarf |
| US8398956B2 (en) | 2007-01-11 | 2013-03-19 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
| US8236949B2 (en) | 2007-07-17 | 2012-08-07 | University Of Delaware | Tetrazine-based bio-orthogonal coupling reagents and methods |
| JP2011503111A (ja) | 2007-11-12 | 2011-01-27 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療 |
| WO2011127149A1 (en) | 2010-04-06 | 2011-10-13 | University Of Utah Research Foundation | Controlled release combination biomaterials |
| US8574629B2 (en) | 2008-08-01 | 2013-11-05 | Anteis S.A. | Injectable hydrogel with an enhanced remanence and with an enhanced ability to create volume |
| WO2010051530A2 (en) | 2008-10-31 | 2010-05-06 | The General Hospital Corporation | Compositions and methods for delivering a substance to a biological target |
| CN102215820A (zh) | 2008-11-17 | 2011-10-12 | 安龙制药公司 | 用于核酸输送系统的可释放融合脂质 |
| BRPI1006246A2 (pt) | 2009-04-16 | 2020-02-04 | Koninl Philips Electronics Nv | "kit para imagem médica marcada e/ou terapias, sonda efetora e método" |
| WO2012012612A2 (en) | 2010-07-23 | 2012-01-26 | University Of Delaware | Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes |
| RU2013121799A (ru) | 2010-10-14 | 2014-11-20 | Конинклейке Филипс Электроникс Н.В. | Набор для претаргетинга, способ и агенты, применяемые в нем |
| WO2012074840A2 (en) | 2010-11-22 | 2012-06-07 | The General Hospital Corporation | Compositions and methods for in vivo imaging |
| EP2654796A1 (en) | 2010-12-21 | 2013-10-30 | Koninklijke Philips N.V. | Agents for clearing biomolecules from circulation |
| EP2522369A1 (en) | 2011-05-09 | 2012-11-14 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| EP2709666B1 (en) | 2011-05-16 | 2021-07-14 | Koninklijke Philips N.V. | Bio-orthogonal drug activation |
| WO2012165462A1 (ja) | 2011-05-31 | 2012-12-06 | 国立大学法人 東京大学 | ハイドロゲル及びその製造方法 |
| ES2393602B1 (es) | 2011-06-09 | 2013-10-02 | Universidad Complutense De Madrid | Materiales biocerámicos para el tratamiento de la osteomielitis. |
| WO2013115885A2 (en) | 2011-11-22 | 2013-08-08 | The Regents Of The University Of Michigan | Synthesizing functionalized dendrimers within biological settings |
| CA2865578C (en) | 2012-02-27 | 2023-01-17 | Amunix Operating Inc. | Xten conjugate compositions and methods of making same |
| US9206271B2 (en) | 2012-03-25 | 2015-12-08 | Wisconsin Alumni Research Foundation | Fully backbone degradable and functionalizable polymers derived from the ring-opening metathesis polymerization (ROMP) |
| WO2013187954A1 (en) | 2012-06-12 | 2013-12-19 | The General Hospital Corporation | Magnetic labeling of bacteria |
| WO2014065860A1 (en) | 2012-10-24 | 2014-05-01 | The General Hospital Corporation | Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions |
| WO2014081299A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| WO2014081300A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| EP2922574B1 (en) * | 2012-11-22 | 2023-05-17 | Tagworks Pharmaceuticals B.V. | Chemically cleavable group |
| WO2014081301A1 (en) * | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| WO2014117001A1 (en) | 2013-01-25 | 2014-07-31 | Memorial Sloan-Kettering Cancer Center | Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides |
| WO2014138186A1 (en) | 2013-03-05 | 2014-09-12 | The Johns Hopkins University | Bioorthogonal two-component delivery systems for enhanced internalization of nanotherapeutics |
| KR102210895B1 (ko) * | 2013-03-08 | 2021-02-02 | 폴리액티바 피티와이 리미티드 | 생리활성 물질의 전달을 위한 폴리머 결합체 |
| JP6600302B2 (ja) | 2013-06-12 | 2019-10-30 | ザ ジェネラル ホスピタル コーポレイション | 標的分子のマルチプレックス検出のための方法、キット、およびシステム、ならびにそれらの使用 |
| WO2014205126A1 (en) * | 2013-06-19 | 2014-12-24 | The Regents Of The University Of California | Chemical structures for localized delivery of therapeutic agents |
| WO2015117235A1 (en) | 2014-02-10 | 2015-08-13 | Mcmaster University | Targeted molecular imaging contrast agents |
| CN106659796B (zh) | 2014-03-14 | 2021-04-30 | 加利福尼亚大学董事会 | Tco缀合物和治疗剂递送方法 |
| ES2951908T3 (es) * | 2014-04-04 | 2023-10-25 | Harvard College | Hidrogeles reticulados por química clic y métodos de uso |
| ES2871029T3 (es) | 2014-04-04 | 2021-10-28 | Harvard College | Dispositivos de liberación de fármacos recargables y procedimientos de uso de los mismos |
| WO2016014799A1 (en) | 2014-07-23 | 2016-01-28 | University Of Iowa Research Foundation | Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy |
| IL256652B2 (en) | 2015-06-29 | 2026-03-01 | Verastem Inc | Dapatinib in combination with an anti-PD1 antibody, anti-PDL1 antibody, or anti-PD1 ligand for use in the treatment of cancer |
| JP6823067B2 (ja) | 2015-09-10 | 2021-01-27 | タンボ・インコーポレイテッド | 生体直交型組成物 |
| ES2983582T3 (es) | 2017-04-07 | 2024-10-23 | Tambo Inc | Composiciones bioortogonales |
-
2016
- 2016-09-12 JP JP2018532532A patent/JP6823067B2/ja active Active
- 2016-09-12 US US15/759,056 patent/US10828373B2/en active Active
- 2016-09-12 WO PCT/US2016/051394 patent/WO2017044983A1/en not_active Ceased
- 2016-09-12 CN CN202311509034.9A patent/CN117567535A/zh active Pending
- 2016-09-12 CN CN201680056941.4A patent/CN108135857A/zh active Pending
- 2016-09-12 AU AU2016321431A patent/AU2016321431C1/en active Active
- 2016-09-12 EP EP16845300.9A patent/EP3346997A4/en active Pending
-
2020
- 2020-09-25 US US17/032,966 patent/US20210015932A1/en not_active Abandoned
-
2021
- 2021-01-06 JP JP2021000729A patent/JP2021073200A/ja not_active Withdrawn
- 2021-12-07 AU AU2021282425A patent/AU2021282425B2/en active Active
- 2021-12-17 US US17/554,792 patent/US12527874B2/en active Active
-
2025
- 2025-01-24 JP JP2025010747A patent/JP2025066807A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stuurman et al. | Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement | |
| JP5746981B2 (ja) | Ｊａｋキナーゼ調節キナゾリン誘導体、及びその使用方法 | |
| RU2414475C2 (ru) | Пролекарства фосфорамидатных алкилаторов | |
| US8357676B2 (en) | Ansamycin formulations and methods of use thereof | |
| ES2660263T5 (en) | Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments | |
| JP2020516621A5 (enExample) | ||
| ES2371411T3 (es) | Nanopartículas de derivados de la gemcitabina. | |
| JP2024521706A5 (enExample) | ||
| JP2009523724A5 (enExample) | ||
| JP2006517939A5 (enExample) | ||
| JP5901634B2 (ja) | キナゾリン化合物及びその使用方法 | |
| CN108135857A (zh) | 生物正交组合物 | |
| JP2009502801A5 (enExample) | ||
| JP2011521911A5 (enExample) | ||
| US11377473B2 (en) | Albumin-binding prodrugs of auristatin E derivatives | |
| JP2017526677A5 (enExample) | ||
| AU2016279051A1 (en) | Delivery systems for controlled drug release | |
| Raj et al. | Synthesis and preliminary in vitro activity of mono-and bis-1 H-1, 2, 3-triazole-tethered β-lactam–isatin conjugates against the human protozoal pathogen Trichomonas vaginalis | |
| JP2012524110A5 (enExample) | ||
| Li et al. | Evaluation of paclitaxel nanocrystals in vitro and in vivo | |
| Okada et al. | Synthesis and antitumor activities of novel benzoylphenylurea derivatives | |
| JP2007513872A5 (enExample) | ||
| HRP20120478T1 (hr) | Formulacije koje sadrže spojeve srodne jorumicinu renieramicinu safracinu ili saframicinu i disaharid za liječenje proliferativnih oboljenja | |
| JP5721806B2 (ja) | 副作用のない抗癌剤 | |
| US12453711B2 (en) | Platinum complex anti-neoplastic agents comprising a cannabinoid ligand |